[go: up one dir, main page]

WO2002062984A1 - Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications - Google Patents

Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications Download PDF

Info

Publication number
WO2002062984A1
WO2002062984A1 PCT/CN2001/000117 CN0100117W WO02062984A1 WO 2002062984 A1 WO2002062984 A1 WO 2002062984A1 CN 0100117 W CN0100117 W CN 0100117W WO 02062984 A1 WO02062984 A1 WO 02062984A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
yeast
biological preparations
specific
immonological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/000117
Other languages
English (en)
Chinese (zh)
Inventor
Kamfu Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIX FOREST BIO-SCIENCE INSTITUTE Ltd
Original Assignee
SIX FOREST BIO-SCIENCE INSTITUTE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIX FOREST BIO-SCIENCE INSTITUTE Ltd filed Critical SIX FOREST BIO-SCIENCE INSTITUTE Ltd
Priority to PCT/CN2001/000117 priority Critical patent/WO2002062984A1/fr
Publication of WO2002062984A1 publication Critical patent/WO2002062984A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention porte sur un procédé de simulation bioélectrique permettant d'activer le gène récessif d'une levure normale afin de la transformer en levure spécifique. Les protéines spécifiques (enzymes) exprimées par la levure spécifique font preuve d'une capacité à activer, moduler et corriger le gène immunitaire dans les lymphocytes B, les lymphocytes T, les lymphocytes K et les lymphocytes NK dont la fonction immunologique est déficiente. En outre, la levure spécifique se présente sous forme de préparation biologique afin de réguler le gène immunitaire pour reconstruire la fonction immunologique du corps, et par la même permettre le rétablissement des patients ayant soufferts de diverses maladies. Les préparations biologiques de cette invention sont indiquées dans la prévention et le traitement de différentes maladies, notamment les différents types de tumeurs, l'urémie, l'hépatite, la démence sénile, diverses maladies gastro-intestinales, le diabète, les troubles du système nerveux, etc. Ces préparations biologiques sont très efficaces et ne présentent pas d'effets toxiques ou secondaires.
PCT/CN2001/000117 2001-02-08 2001-02-08 Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications Ceased WO2002062984A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/000117 WO2002062984A1 (fr) 2001-02-08 2001-02-08 Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/000117 WO2002062984A1 (fr) 2001-02-08 2001-02-08 Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications

Publications (1)

Publication Number Publication Date
WO2002062984A1 true WO2002062984A1 (fr) 2002-08-15

Family

ID=4574771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000117 Ceased WO2002062984A1 (fr) 2001-02-08 2001-02-08 Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications

Country Status (1)

Country Link
WO (1) WO2002062984A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375652A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour des sujets infectés par le VIH
EP1375651A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour l'activation et la prolifération des globules blancs
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US6964864B2 (en) 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6979562B2 (en) 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6984507B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US6987012B2 (en) 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US6989253B2 (en) 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7078202B2 (en) 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US7201906B2 (en) 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204987B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223402B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223405B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US7223400B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7226600B2 (en) 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7259001B2 (en) 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US7297522B2 (en) 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
WO2011023769A1 (fr) * 2009-08-26 2011-03-03 Mb Milmed Ab Composition destinée au traitement de maladies ou de troubles neurodégénératifs, méthode et utilisation impliquant de la levure électromagnétiquement irradiée

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU902462A1 (ru) * 1980-03-26 1982-08-15 Отдел Биологии Дагестанского Филиала Ан Ссср Способ выращивани дрожжей
SU1514777A1 (ru) * 1987-06-30 1989-10-15 Inst Molekulyarnoj Biolog An S Способ получения биомассы дрожжей 5асснакомусе5 секеу151аб
CN1185484A (zh) * 1996-12-11 1998-06-24 阿尔瓦罗·V·皮卡卢加 调节细胞行为的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU902462A1 (ru) * 1980-03-26 1982-08-15 Отдел Биологии Дагестанского Филиала Ан Ссср Способ выращивани дрожжей
SU1514777A1 (ru) * 1987-06-30 1989-10-15 Inst Molekulyarnoj Biolog An S Способ получения биомассы дрожжей 5асснакомусе5 секеу151аб
CN1185484A (zh) * 1996-12-11 1998-06-24 阿尔瓦罗·V·皮卡卢加 调节细胞行为的方法

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375652A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour des sujets infectés par le VIH
EP1375651A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour l'activation et la prolifération des globules blancs
US7204987B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US7172888B2 (en) 2003-06-11 2007-02-06 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US7226600B2 (en) 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984507B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US6987012B2 (en) 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US6989253B2 (en) 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7223400B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7163813B2 (en) 2003-06-11 2007-01-16 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7172889B2 (en) 2003-06-11 2007-02-06 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US7201906B2 (en) 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223405B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US7223402B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7078202B2 (en) 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US7208159B2 (en) 2003-11-18 2007-04-24 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6979562B2 (en) 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6964864B2 (en) 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US7259001B2 (en) 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US7297522B2 (en) 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
WO2011023769A1 (fr) * 2009-08-26 2011-03-03 Mb Milmed Ab Composition destinée au traitement de maladies ou de troubles neurodégénératifs, méthode et utilisation impliquant de la levure électromagnétiquement irradiée
CN102481368A (zh) * 2009-08-26 2012-05-30 密美德有限公司 包含电磁辐射的酵母的治疗神经变性疾病或病症的组合物、方法和用途
JP2013503138A (ja) * 2009-08-26 2013-01-31 エムビー ミルメド エービー 電磁放射酵母を含む神経変性疾患または障害の処置のための組成物、方法および使用
CN102481368B (zh) * 2009-08-26 2014-01-29 密美德有限公司 包含电磁辐射的酵母的治疗神经变性疾病或病症的组合物、方法和用途
US9320768B2 (en) 2009-08-26 2016-04-26 Milmed Ab Composition for treatment of neurodegenerative diseases or disorders, method and use comprising electromagnetically irradiated yeast

Similar Documents

Publication Publication Date Title
WO2002062984A1 (fr) Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications
WO2002062981A1 (fr) Immunoregulateur humain de levure et son procede de preparation
Balakrishnan et al. The role of Amaranth, quinoa, and millets for the development of healthy, sustainable food products—a concise review
WO2002062983A1 (fr) Levure faisant preuve d'une activite immunoregulatrice des lymphocytes t, son procede de preparation et ses applications
WO2002062985A1 (fr) Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications
WO2002062982A1 (fr) Levure faisant preuve d'une activite immunoregulatrice des lymphocytes b, son procede de preparation et ses applications
Copenhaver et al. IL-1R signaling enables bystander cells to overcome bacterial blockade of host protein synthesis
Li et al. Investigation of Chlorella pyrenoidosa protein as a source of novel angiotensin I-converting enzyme (ACE) and dipeptidyl peptidase-IV (DPP-IV) inhibitory peptides
Osiewacz et al. Mitochondrial quality control: impact on aging and life span-a mini-review
EP4269561A3 (fr) Modalites ameliorees du traitement des maladies degeneratives de la retine
WO2007117438A3 (fr) Méthodes de production d'une protéine fonctionnelle à partir d'un adn présentant une mutation non-sens et traitement des troubles associés
Sagu et al. Comprehensive characterization and relative quantification of α-amylase/trypsin inhibitors from wheat cultivars by targeted HPLC-MS/MS
Hu et al. Purification and identification of novel xanthine oxidase inhibitory peptides derived from round scad (Decapterus maruadsi) protein hydrolysates
WO2007150067A3 (fr) Programme nutritionnel et d'exercice basé sur le génotype d'apo e génétique individuel d'une personne
WO2005058945A3 (fr) Variants genetiques codant pour des proteines issues de la voie metabolique de produits chimiques fins
Chen et al. Development and optimization of djulis sourdough bread fermented by lactic acid bacteria for antioxidant capacity
Laurent-Babot et al. Should research on the nutritional potential and health benefits of fermented cereals focus more on the general health status of populations in developing countries?
Kęska et al. Stability of antiradical activity of protein extracts and hydrolysates from dry-cured pork loins with probiotic strains of LAB
Ulvestad Psychoneuroimmunology: the experiential dimension
Cappello et al. Identification and selection of prospective probiotics for enhancing gastrointestinal digestion: Application in pharmaceutical preparations and dietary supplements
Kawa et al. Locomotor activity, object exploration and space preference in children with autism and Down syndrome
Starzyńska-Janiszewska et al. Phenolic profile, antioxidant activity and amino acid composition of moringa leaves fermented with edible fungal strains
Okabe et al. Autism Spectrum Disorder-and/or Intellectual Disability-Associated Semaphorin-5A Exploits the Mechanism by Which Dock5 Signalosome Molecules Control Cell Shape
WO2006122971A3 (fr) Traitement de maladies a l'aide d'un systeme d'expression regulee, ameliore
Garrido-Ortiz et al. Production of Protein Hydrolysates with Antioxidant and Antihypertensive Activity from Edible Larvae of Aegiale hesperiaris and Comadia redtenbacheri

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP